कंपनी का अवलोकन
Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical entity focused on developing orally bioavailable small molecule therapeutic products intended for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction within the Israeli market. The company functions within the Healthcare sector and the specific Biotechnology industry, positioning itself to leverage research and development capabilities to address significant medical needs. Its current operational scale is characterized by a market capitalization of $6.88M, annual revenue of $405,000, and an employee count of 5. These financial figures indicate that the company is a micro-cap entity with very limited revenue generation relative to its market valuation, suggesting it is in an early-stage development phase where capital allocation prioritizes research over commercial expansion. The disparity between the $6.88M market cap and the $405,000 in annual revenue highlights that the company's valuation is driven primarily by its pipeline potential and clinical-stage assets rather than current cash-flow-generating operations.
वित्तीय स्वास्थ्य
The company reported revenue of $405,000 and a net income of $-9,828,000 over the trailing twelve months, while EBITDA stood at $-9,926,000. The substantial negative gap between the minimal revenue of $405,000 and the net loss of $-9,828,000 reveals an extremely high cost structure typical of early-stage biotechnology firms, where research, development, and administrative expenses far exceed current sales. Free cash flow for the period was $-4,985,750, which signifies a heavy reliance on external financing or cash reserves to sustain operations and fund the clinical development of its drug candidates. The company maintains a cash balance of $8.54M against total debt of $71,000, indicating a strong liquidity position despite the ongoing losses. The debt-to-equity ratio of 1.27 suggests that the company utilizes leverage, yet the significant cash cushion provides a buffer against the fixed obligations associated with that debt. The current ratio of 3.46 indicates robust short-term liquidity, as current assets significantly outweigh current liabilities, allowing the firm to meet its immediate financial obligations without distress. Return on Equity is reported at -178.2% and Return on Assets at -66.7%, metrics that reveal management is currently consuming shareholder capital and asset base to fund operations rather than generating immediate returns.
मूल्यांकन आकलन
The trailing P/E ratio is N/A due to the lack of positive earnings, while the forward P/E is listed as -4.01, implying that the market prices the stock based on future earnings expectations that are currently projected to remain negative. The price-to-book ratio stands at 0.69, indicating that the market values the company at approximately 69% of its net book value, which often suggests the stock may be undervalued relative to its assets or that the asset base has significant intangible limitations. The price-to-sales ratio is 16.98, a metric that suggests the market is willing to pay a significant premium for each dollar of sales given the high risk and high growth potential associated with the biotechnology sector. The EV/EBITDA multiple is -0.41, a negative figure that reflects the company's unprofitable status and indicates that traditional enterprise value multiples are not applicable in a conventional sense. The stock has traded between a 52-week high of $36.40 and a 52-week low of $2.93, placing the current valuation context within a wide volatility range that reflects the speculative nature of clinical-stage assets. The beta value of -0.10 is anomalous for equities, suggesting that the stock price moves inversely to the broader market or exhibits a unique risk profile distinct from standard market correlations.
Growth & Income
Revenue growth year-over-year is -43.3%, while earnings growth is N/A, indicating that the company is currently contracting in terms of top-line sales rather than expanding. The negative revenue growth suggests that the company may be in a transition phase where revenue recognition patterns are shifting, potentially due to the completion of clinical trials or changes in commercialization strategy. As a non-dividend payer, the company does not distribute a dividend yield, and the payout ratio is 0.0%, meaning all available earnings and cash reserves are reinvested directly into the research and development pipeline to pursue growth objectives. This reinvestment strategy is standard for clinical-stage biopharmaceuticals, where capital is required to advance drug candidates through regulatory approval processes rather than being returned to shareholders. The overall growth and income profile for Can-Fite BioPharma is characterized by a lack of current profitability and revenue contraction, with the primary focus on preserving cash reserves to sustain the development of its therapeutic products for cancer, liver diseases, and erectile dysfunction.